Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the company. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $28.00.

A number of research analysts have commented on the company. HC Wainwright set a $27.00 price objective on Lexicon Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Lexicon Pharmaceuticals in a report on Wednesday, April 5th. Citigroup Inc upped their price objective on Lexicon Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, March 7th. Wedbush upped their price objective on Lexicon Pharmaceuticals from $33.00 to $38.00 and gave the company an “outperform” rating in a report on Wednesday, March 1st. Finally, Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 17th.

TRADEMARK VIOLATION NOTICE: “Lexicon Pharmaceuticals, Inc. (LXRX) Given Average Recommendation of “Buy” by Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/05/26/lexicon-pharmaceuticals-inc-lxrx-given-average-recommendation-of-buy-by-analysts.html.

Several hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its stake in Lexicon Pharmaceuticals by 24.1% in the third quarter. Bank of New York Mellon Corp now owns 240,922 shares of the biopharmaceutical company’s stock worth $4,353,000 after buying an additional 46,756 shares during the last quarter. Prudential Financial Inc. bought a new stake in Lexicon Pharmaceuticals during the third quarter worth $895,000. BlackRock Inc. increased its stake in Lexicon Pharmaceuticals by 478.8% in the third quarter. BlackRock Inc. now owns 18,932 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 15,661 shares during the last quarter. BlackRock Fund Advisors increased its stake in Lexicon Pharmaceuticals by 5.3% in the third quarter. BlackRock Fund Advisors now owns 2,468,459 shares of the biopharmaceutical company’s stock worth $44,605,000 after buying an additional 124,460 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in Lexicon Pharmaceuticals by 38.7% in the third quarter. TIAA CREF Investment Management LLC now owns 294,598 shares of the biopharmaceutical company’s stock worth $5,323,000 after buying an additional 82,171 shares during the last quarter.

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 14.56 on Friday. The company’s market cap is $1.53 billion. The firm’s 50-day moving average is $15.14 and its 200 day moving average is $15.15. Lexicon Pharmaceuticals has a 1-year low of $13.01 and a 1-year high of $19.62.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Friday, March 3rd. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.20. Lexicon Pharmaceuticals had a negative return on equity of 9.46% and a negative net margin of 11.87%. The firm had revenue of $23 million for the quarter, compared to analyst estimates of $15.56 million. During the same period in the prior year, the firm posted $0.76 EPS. The company’s revenue for the quarter was down 81.9% on a year-over-year basis. Equities analysts expect that Lexicon Pharmaceuticals will post ($1.49) EPS for the current fiscal year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

12 Month Chart for NASDAQ:LXRX

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.